2-amino-4-(pentyloxy)pteridine-6(5H)-thione | 146196-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-amino-4-(pentyloxy)pteridine-6(5H)-thione
• 英文别名: 2-amino-4-n-pentyloxy-6(5H)pteridinethione；2-amino-4-pentoxy-5H-pteridine-6-thione
• CAS: 146196-29-4
• 化学式: C₁₁H₁₅N₅OS
• 分子量: 265.339
• InChiKey: YZCFMRABBJISSV-UHFFFAOYSA-N

物化性质

• 沸点：
  510.3±60.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-amino-4-(pentyloxy)pteridine-6(5H)-thione 在 sodium hydroxide 作用下， 反应 0.5h， 以88%的产率得到thioxanthopterin disodium salt
  参考文献：
  名称：

  蝶啶。第XCVII部分。6-硫代黄嘌呤蝶呤和7-硫代异黄嘌呤蝶呤的合成及性质†

  摘要：

  6- Thioxanthopterin（13）在从开始的四个步骤合成2-氨基-4-（penthyloxy）蝶啶（3）通过8氧化物4，其随后互向6-氯（7）和6-硫代衍生物（12）和戊氧基的最终水解。通过碱性水解类似地从2-氨基-4-（戊氧基）蝶啶-7（8 H）-硫酮（14）衍生出7-硫代异黄蝶呤（15）。将各种6-和7-噻吩啶甲基化，得到相应的6-（10，11）和7-（甲硫基）衍生物（16，17）。新合成的化合物通过元素分析，紫外光谱以及酸性和碱性p K a值的测定来表征。详细讨论光谱关系。

  DOI：

  10.1002/hlca.19920750718
• 作为产物：
  描述：

  2,4-pyrimidinediamine, 5-nitroso-6-(pentyloxy) 在 sodium hydrogensulfide 、 ammonium sulfide 、 双氧水 、 溶剂黄146 、 乙酰氯 、 三氟乙酸 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 150.25h， 生成 2-amino-4-(pentyloxy)pteridine-6(5H)-thione
  参考文献：
  名称：

  蝶啶。第XCVII部分。6-硫代黄嘌呤蝶呤和7-硫代异黄嘌呤蝶呤的合成及性质†

  摘要：

  6- Thioxanthopterin（13）在从开始的四个步骤合成2-氨基-4-（penthyloxy）蝶啶（3）通过8氧化物4，其随后互向6-氯（7）和6-硫代衍生物（12）和戊氧基的最终水解。通过碱性水解类似地从2-氨基-4-（戊氧基）蝶啶-7（8 H）-硫酮（14）衍生出7-硫代异黄蝶呤（15）。将各种6-和7-噻吩啶甲基化，得到相应的6-（10，11）和7-（甲硫基）衍生物（16，17）。新合成的化合物通过元素分析，紫外光谱以及酸性和碱性p K a值的测定来表征。详细讨论光谱关系。

  DOI：

  10.1002/hlca.19920750718

文献信息

• Structural Requirements for Inhibition of the Neuronal Nitric Oxide Synthase (NOS-I):  3D-QSAR Analysis of 4-Oxo- and 4-Amino-Pteridine-Based Inhibitors
  作者：Hans Matter、Peter Kotsonis、Otmar Klingler、Hartmut Strobel、Lothar G. Fröhlich、Armin Frey、Wolfgang Pfleiderer、Harald H. H. W. Schmidt

  DOI：10.1021/jm020074g

  日期：2002.7.1

  The family of homodimeric nitric oxide synthases (NOS I-III) catalyzes the generation of the cellular messenger nitric oxide (NO) by oxidation of the substrate L-arginine. The rational design of specific NOS inhibitors is of therapeutic interest in regulating pathological NO levels associated with sepsis, inflammatory, and neurodegenerative diseases. The cofactor (6R)-5,6,7,8-tetrahydrobiopterin (H(4)Bip) maximally activates all NOSs and stabilizes enzyme quaternary structure by promoting and stabilizing dimerization. Here, we describe the synthesis and three-dimensional (3D) quantitative structure-activity relationship (QSAR) analysis of 65 novel 4-amino- and 4-oxo-pteridines (antipterins) as inhibitors targeting the H(4)Bip binding site of the neuronal NOS isoform (NOS-I). The experimental binding modes for two inhibitors complexed with the related endothelial NO synthase (NOS-III) reveal requirements of biological affinity and form the basis for ligand alignment. Different alignment rules were derived by building other compounds accordingly using manual superposition or a genetic algorithm for flexible superposition. Those alignments led to 3D-QSAR models (comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA)), which were validated using leave-one-out cross-validation, multiple analyses with two and five randomly chosen cross-validation groups, perturbation of biological activities by randomization or progressive scrambling, and external prediction. An iterative realignment procedure based on rigid field fit was used to improve the consistency of the resulting partial least squares models. This led to consistent and highly predictive 3D-QSAR models with good correlation coefficients for both CoMFA and CoMSIA, which correspond to experimentally determined NOS-II and -III H(4)Bip binding site topologies as well as to the NOS-I homology model binding site in terms of steric, electrostatic, and hydrophobic complementarity. These models provide clear guidelines and accurate activity predictions for novel NOS-I inhibitors.